TrialDiabetes, obesity & metabolism2006

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

L Blonde et al.PubMed ↗Publisher ↗

No numbers read from the abstract.